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HaCaT keratinocyte cultures were exposed to twelve hydrophilic anthralin 
derivatives 1 to 12 with substituents at C-l and C-8 of the anthrone skeleton, 
of one H at C-10 and of both H's at C-10 by lacton rings (fig. 1). After 3 uM 
treatment growth was determined by cellular protein content, ^-thymidine-
and 14C-amino-acid-uptake and cytotoxicity by the release of cytoplasmic 
LDH into the culture medium.- In comparison to acetone control (100%) 
anthralin suppressed mean protein content, as well as DNA- and protein-syn-
thesis to 33, 28, and 21%, respectively, and the drug revealed an enzyme 
release of 660%. In relation to the parent drug we found similar cell growth 
inhibitory effects of compounds 4, 6, 8, 9, 10, and 12. Deriv. 4, 8, and 10 
were, however, to some extent less cytotoxic than anthralin, whereas deriv. 
6, 9, and 12 were in the same range. An extreme suppression of growth 
parameters which differed from the anthralin effect by a factor 0.5-0.8 was 
caused by deriv. 11, showing the same cytotoxicity. Deriv. 1, 2, 3,5, and 7 
did not demonstrate any cytotoxicity. Concerning growth parameters, deriv. 
2 induced a slight stimulation, deriv. 3 and 7 were completely ineffective, 
deriv. 1 and 5 induced slightly to moderately inhibited proliferation but both 
being much less effective than anthralin. These data indicate that the "mini-
mum structure" concept by Krebs and Schaltegger - claiming l-hydroxy-9-
anthrone as a precondition for clinical antipsoriatic potency - is not valid at 
least in cell-biological tests and point toward possible usefulness of some 
experimental model compounds as alternative antipsoriatics. 
Beurteilung von Struktur-Wirkungs-Beziehungen neuer Anthralin-De-
rivate aufgrund der Zellwachstumshemmung und Zytotoxizität in 
Humankeratinozyten-Kulturen 
In HaCaT Keratinozyten-Kulturen wurden zwölf hydrophile Dithranol-Deri-
vate 1 bis 12 untersucht, die Substituenten an C-l und C-8 des Anthronge-
rüsts, an C-2, an Stelle eines H-Atoms an C-10 und an Stelle beider H an 
C-10 Lacton-Ringe aufweisen (Fig. 1). Nach der Behandlung mit 3 u.M 
Substanz wurde das Zellwachstum bestimmt anhand des zellulären Protein-
gehalts, 3H-Thymidin- und 14C-Aminosäuren-Einbaus; die Zytotoxizität war 
durch die extrazelluläre Freisetzung der zytoplasmatischen Lactatdehydroge-
nase erfaßbar.- Im Vergleich zu der Aceton-Kontrolle (100%) erniedrigte 
Dithranol den Proteingehalt, die DNA- und Protein-Synthese im Mittel auf 
33, 28 bzw. 21%, dabei kam es zu einer Enzymfreisetzung von 660%. Im 
Vergleich zu Dithranol fanden wir ähnliche Hemmungen des Zellwachstums 
für die Derivate 4,6,8,9,10 und 12. Die Derivate 4,8 und 10 waren jedoch 
weniger zytotoxisch als Dithranol, wohingegen die Derivate 6, 9 und 12 
diesbezüglich im gleichen Bereich lagen. Eine extreme Hemmung der 
Wachstumsparameter, wobei diese vom Dithranol-Effekt um einen Faktor 
0.5 bis 0.8 abwichen, ergab sich für das Derivat 11, welches gleich stark 
zytotoxisch wirkte. Die Derivate 1, 2, 3, 5 und 7 waren nicht zytotoxisch. 
Bezüglich der Wachstumsparameter ließ sich feststellen, daß das Derivat 2 
leicht stimulierte, die Derivate 3 und 7 vollständig unwirksam waren und die 
Derivate 1 und 5 das Zellwachstum leicht bis mäßig hemmten, aber die 
Hemmung viel geringer ausgeprägt war als die durch Dithranol. Die Ergeb-
nisse zeigen, daß a) das von Krebs und Schaltegger begründete Konzept der 
"Minimalstruktur" - demzufolge die l-Hydroxy-9-anthron-Struktur eine Vor-
aussetzung für klinische antipsoriatische Wirksamkeit eines Anthrons dar-
stellt - zumindest für zellbiologische Tests nicht allgemein gültig ist und 
weisen b) auf eine mögliche weitergehende Bedeutung einzelner dieser Mo-
dell-Substanzen als antipsoriatische Alternativ-Therapeutika hin. 
Although anthralin (syn. dithranol) is a classic topical antipsoriatic, there 
is still a controversial debate concerning its exact biochemical mode of 
action. The drug is known to suppress various parameters of cell metabo-
lism, e.g. DNA-replication and -repair1'2'3'4), protein-synthesis3), mitochon-
drial respiration5'6'7'8*, activities of cytosolic glucose-6-phosphate-dehy-
drogenase9'10'11*, calmodulin l2\ thioredoxin-reductase13'14), plasminogen-
activator15), arachidonic acid lipoxygenase16), and superoxide anion gener-
ation in neutrophils17). Comparative dose response studies have favored 
mitochondrial respiration as the primary cellular target 1 8 ' 1 9 « 2 0 ) . With regard 
to the sequel of subcellular drug effects, to a great extent the experimental 
difficulties derive from anthralin's instability through oxidation generating 
a cascade of radicals assumed to be the immediate effectors of cytotox-
icity 2 1 ' 2 2 ^. 
Much of the experimental work is impeded by the low 
degree of solubility of anthralin in aqueous systems9'24*. 
This could be overcome by developing and using hydro-
philic anthralin derivatives as drug models. Therefore, the 
present study deals with twelve more aqueous soluble an-
thralin derivatives (deriv. 1 to 12) with hydrophilic groups 
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Figure 1: Structural formulas of anthralin, bianthrone, danthrone, and the 
anthralin derivatives 1 to 12 used in this study. 
synthesized recently24'25). This panel of derivatives (fig. 1) 
contains a 1,8-dimethoxy-compound [1] as well as C-2 [2 to 
5] and C-10 [6 to 12] substituted anthrones. The reason for 
in vitro screening is the ongoing search for a derivative 
having antipsoriatic efficacy but lacking skin irritancy or 
staining of skin (clothes), which both still represent the 
main disadvantages of clinical anthralin application. 
With regard to psoriatic epidermal hyperproliferation we 
used HaCaT cells, a rapidly multiplying human keratinocyte 
line 2 6 ), as an assay system. This has been described as being 
extremely sensitive to anthralin as evidenced by a 50% in-
hibition concentration (IC50) of 0.2 |iiM for DNA synthesis 
and by a significant release of lactate dehydrogenase (indi-
cating cytotoxicity) at a relatively low concentration of 0.3 
| I M 2 7 ) . 
Abbreviations 
DMEM: Dulbecco's modified Eagle's medium G-6-PDH: glucose-6-
phosphate dehydrogenase IC50: 50% inhibition concentration LDH: lactate 
dehydrogenase 
Test Compounds 
Figure 1 shows the structural formulas of anthralin, its oxidation pro-
ducts bianthrone and danthrone, and twelve anthralin derivatives applied in 
this study. All test compounds were dissolved in acetone at 3.0 mM under 
light protection. The solutions were then diluted 1:1000 with Dulbecco's 
modified Eagle's medium (DMEM, Flow Cat. No. 12-332-54) which was 
used serum-free in order to avoid binding or inactivation of the test com-
pounds by serum constituents3*. All solutions were prepared immediately 
before use. 
HPLC-Monitoring of Anthralin Stability 
With regard to our special cell culture conditions we prechecked the 
stability of anthralin which was dissolved at 3 ^ M in 0.1% acetone and 
serum-free DMEM at 37°C under 10% C 0 2 . After adding the drug to the 
cell-free medium, several samples were taken and analysed by HPLC dur-
ing the following 240 min25*. 
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Figure 2: Decay kinetics of anthralin which was dissolved at 3 uM in 
serum-free Dulbecco's modified Eagle's medium (DMEM) containing 
0.1% acetone (37°C, 10% C0 2 ) . The drug and its main oxidation products 
bianthrone and danthrone were detected by HPLC 4 2 * and recorded as relati-
ve amounts of total substance. 
Cell-Culture 
HaCaT cells** were seeded in Greiner 24-well-multidishes and grown in 
DMEM, supplemented with 1% antibiotic-antimycotic-solution (Gibco 
Cat. No. 043-5240H), 4 mM L-glutamine (Gibco Cat No. 043-5030H) and 
10% fetal calf serum (Gibco Cat. No. 011-6290H) at 37°C in a humidified 
atmosphere of 10% CO2. Exposure to test compounds was performed on 
subconfluent cultures at log-growth-phase, which was reached one day 
after plating of 4 x 104 cells per 1,8 cm 2 (series 1) or three days after 
plating of 1 x 104 cells (series 2). The cultures were rinsed two times with 
DMEM and incubated with 3.0 | iM test compound in DMEM (0.1% 
acetone, as described above) for 30 min; control cultures were exposed to 
DMEM containing 0.1% acetone. Subsequently, the supernatants were dis-
HaCaT cells were kindly provided by Dr. N.E. Fusenig (German Cancer Research Center, Heidelberg, FRG). 
carded and cultivation was continued in the complete growth medium in-
cluding serum until the 2nd day after the test compound exposure. 
For measurement of cytotoxicity by LDH release we employed a proto-
col which has been described in detail27*.- In brief, 1.8 x 106 HaCaT cells 
were seeded in a culture flask (75 cm2, Falcon) and grown to post-con-
fluency for 14 days. The cells were incubated with the test compounds for 
30 min (see above) and thereafter kept in 13 ml of fresh DMEM during the 
following 24 h (see below). 
Measurement of Cellular Protein 
48 h after exposure with the test compounds, the protein content of 
attached cells was determined by a modified Bradford method3,28*. In brief, 
the cultures were rinsed twice with methanol and dried in the air. The cells 
were overlayered with 1.5 ml of 0.5 N NaOH per well and kept under 
occlusion by means of a Parafilm foil in order to prevent evaporation. After 
the wells had been gently agitated at room temp, for 16 h, the probes were 
stained with BioRad-reagent (Cat. No. 500-0006) and photometrically 
measured at 595 nm against bovine serum albumin standard. 
Incorporation of3H-thymidine and 14C-amino-acids 
48 h after treatment with the test compounds cultures were pulse labeled 
(2 h) simultaneously with 1.0 jxCi methyl-3H-thymidine (specific activity 
77.9 Ci/mmol, NEN DuPont, 6380 Bad Homburg, FRG, NET-027Z) and 
0.5 uCi 14C-amino-acids (mixture of 15 different amino acids, specific 
activity 1.85 GBq/milligramatom of carbon, Amersham, 3300 Braun-
schweig, FRG, CFB.104) in 1 ml DMEM per well of the multidish. Cells 
were then trypsinized with 0.05% trypsin/0.02% EDTA (Gibco Cat. No. 
043-5300M) for 45 min at 37°C and precipitated with 5% trichloroacetic 
acid. The cell material was harvested by an Inotech apparatus and counted 
in a Rackbeta scintillation counter (LKB) using the two channel mode. The 
incorporation of 3H-thymidine and 14C-amino-acids per well was taken as a 
measure for DNA and protein synthesis of the cultures3'29*. 
Lactate Dehydrogenase (LDH) Release Assay 
The supernatants of cultures which had been treated with the test com-
pounds 24 h previously were collected for the determination of the extra-
cellular LDH activity. According to the recommendations of the German 
Society for Clinical Chemistry an optimized standard method of the 
photometric measurement was performed using a Boehringer Mannheim 
test kit for BM/Hitachi system 737 2 7 » 3 0 ' 3 1 ) . 
Morphological Monitoring 
48 h after incubation, cultures were examined by phase contrast micro-
scopy. The morphological evaluation was performed with special regard to: 
a) density of attached cells, b) loss of regular "cobble-stone-pattern" with 
widened intercellular spaces, c) extent of cell detachment, d) alteration of 
cell shape, e.g. impeded cell-spreading, ballooning, pycnotic shrinking, 
fragmentation, and e) cytoplasmic changes, e.g. vacuolization or condensa-
tion32'33*. 
Study Design and Statistical Analysis 
The test compounds were studied for their influence on 
the four mentioned parameters (protein content, thymidine-
and amino-acid-incorporation, LDH release) in two series of 
investigations. Series 1 consisted of a simultaneous testing 
of bianthrone, danthrone, deriv. 1, 3, 5, 7, 8, 10, and 12; 
deriv. 2, 4, 6, 9, and 11 were tested in series 2. Both series 
included a control with 0.1% acetone as well as a standard 
with anthralin. Growth studies were conducted in at least 
six culture wells in three independent experiments (total: 18 
cultures) for each compound, and the enzyme release 
studies were performed in three culture flasks, each in tripli-
cate (total: 9 cultures). For each experiment and parameter 
the mean value of the acetone control was taken as 100%. 
Statistical comparisons on the relative data pooled from the 
three experiments were performed according to Mann and 
Whitney (U-test34)). Multiple comparisons required Bonfer-
roni's adjustment35*, with an overall level of significance a 
< 0.05 corresponding to p < 0.005 (series 1) and p < 0.0083 
(series 2). 
Results 
HPLC monitoring revealed that under cell-free conditions 
anthralin dissolved with acetone 0.1% in DMEM (37°C, 
10% C0 2 ) decomposed at a rate of 31% at 5 min, 78% at 15 
min, 87% at 30 min, and 98% at 70 min. The main oxida-
tion products found were bianthrone and danthrone reaching 
a plateau of 41% and 24% at 48 and 60 min, respectively. 
These data (fig. 2) prompted us to restrict the exposure time 
for all compounds to 30 min. 
The data of the protein content, 3H-thymidine- and 1 4 C -
amino-acid-incorporation of attached cells are compiled in 
table 1, 2, and 3. Setting the values for acetone at 100% 
(control) we found a similar inhibition of cell growth by 
anthralin in both series 1 and 2, that means a reduced mean 
cellular protein content of 31 and 35%, DNA-synthesis of 
19 and 36% as well as protein-synthesis of 16 and 25%, 
respectively. Statistical comparison of these data for 
acetone and anthralin with the growth values of the different 
test compounds are shown in tables 1,2, and 3. 
In both series the mean LDH release by anthralin ex-
ceeded that of the acetone controls by a factor > 6. These 
results, which represent a measure for cytotoxicity, are cal-
culated on a percentage level in table 4, which also shows 
statistical comparison of the different compounds with the 
acetone control and anthralin. 
In the phase contrast microscope we found morphological 
alterations which were strictly correlated with the above 
mentioned effects on cell growth and toxicity-dependent 
LDH release of the tested compounds. Thus the state of cell 
growth and the cytotoxicity were reflected by the density of 
adherent keratinocytes and the cell degeneration phenomena 
described in detail under "Material and Methods". Repre-
sentative examples of the morphological findings after treat-
ment with the rather effective deriv. 10 and the uneffective 
deriv. 3 are given in fig. 3. 
Discussion 
"Minimum structure" concept 
Krebs and Schaltegget36*3^ tested about 30 different an-
thrones for their efficacy in psoriatic patients. They found a 
potent effect only for anthralin, chrysarobin (1,8-dihydroxy-
3-methyl-9-anthrone), l-hydroxy-9-anthrone, and 1,8,9-
Figure 3: Phase contrast microscopy of cultured HaCaT keratinocytes two days after 30 min treatment 
with 0.1% acetone (A), with 3.0 u M anthralin (B), and with 3.0 u M of 10 (C) and 3 (D). In comparison to 
the acetone control, anthralin and deriv. 10 revealed signs of marked inhibition of cell growth and cyto-
toxicity, i.e. reduced density of attached cells, increased number of detached and deformed cells. With 
deriv. 3 there was no obvious difference compared to the control (60x). 
Table 1: Protein content of attached HaCaT keratinocytes per culture two days after exposure to 
anthralin derivatives 1 to 12. Significant differences at an overall level a < 0.05 are indicated by 
asterisks. 
Incubation Series Protein content 
Test Compound Percentage Statistical Comparison (p) 
(mean ± s. d.) of the Test compound 
versus 
Acetone Anthralin 
Acetone 100.0 ± 2.5 0.0000* 
Anthralin 1 31.0 ± 15.4 0.0000* -
Bianthrone 1 31.8 ± 12.8 0.0000* 0.4619 
Danthrone 1 89.4 ± 12.0 0.0014* 0.0000* 
Deriv. 1 1 90.8 ± 8.8 0.0021* 0.0000* 
Deriv. 3 1 103.0 ± 5.1 0.0736 0.0000* 
Deriv. 5 1 67.0 ± 9.9 0.0000* 0.0000* 
Deriv. 7 1 106.3 ± 10.0 0.0290 0.0000* 
Deriv. 8 1 28.1 ± 8.5 0.0000* 0.9129 
Deriv. 10 1 27.3 ± 7.3 0.0000* 0.9626 
Deriv. 12 1 24.5 ± 7.4 0.0000* 0.3888 
Acetone 2 100.0 ± 10.8 - 0.0000* 
Anthralin 2 34.9 ± 7.9 0.0000* -
Deriv. 2 2 107.6 ± 16.2 0.0024* 0.0000* 
Deriv. 4 2 35.5 ± 14.0 0.0000* 0.5657 
Deriv. 6 2 47.9 ± 24.6 0.0000* 0.0120 
Deriv. 9 2 32.0 ± 12.2 0.0000* 0.1447 
Deriv. 11 2 26.8 ± 10.5 0.0000* 0.0014* 
Table 2: DNA-synthesis per culture two days after exposure of HaCaT keratinocytes to various 
test compounds. Significant differences at an overall level a < 0.05 are indicated by asterisks. 
Incubation Series 3H-Thymidine Incorporation 
Test Compound Percentage Statistical Comparison (p) 
(mean ± s. d.) of the Test compound 
versus 
Acetone Anthralin 
Acetone 100.0 ± 19.1 0.0000* 
Anthralin 1 19.2 ± 12.3 0.0000* -
Bian throne 1 33.2 ± 24.0 0.0000* 0.0186 
Danthrone 1 94.1± 25.6 0.3888 0.0000* 
Deriv. 1 1 93.9 ± 20.7 0.3550 0.0000* 
Deriv. 3 1 101.9 ± 12.8 0.2788 0.0000* 
Deriv. 5 1 75.6 ± 17.0 0.0001* 0.0000* 
Deriv. 7 1 108.7 ± 10.4 0.0847 0.0000* 
Deriv. 8 1 12.3 ± 3.4 0.0000* 0.0320 
Deriv. 10 1 11.4 ± 4.3 0.0000* 0.0083 
Deriv. 12 1 7.8 ± 4.8 0.0000* 0.0000* 
Acetone 2 100.0 ± 26.4 - 0.0000* 
Anthralin 2 36.1 ± 8.5 0.0000* -
Deriv. 2 2 148.4 ±44.1 0.0000* 0.0000* 
Deriv. 4 2 38.1 ± 7.0 0.0000* 0.1710 
Deriv. 6 2 48.5 ± 15.8 0.0000* 0.0010* 
Deriv. 9 2 21.1 ± 5.9 0.0000* 0.0000* 
Deriv. 11 2 22.5 ± 11.5 0.0000* 0.0000* 
triacetoxy-anthracene; the last had been introduced by HeU 
Her and Whitefield3S\ Krebs and coworker claimed 1-hy-
droxy-9-anthrone as the "minimum structure" of an an-
throne required for clearing up psoriasis. In detail this 
"minimum structure" should consist of a) a hydroxy group 
at C - l , b) a carbonyl group at C-9, and c) a C-10 methylene 
group (two hydrogens). Determining the activity of isolated 
glucose-6-phosphate dehydrogenase (G-6-PDH), which as a 
key enzyme for hexosemonophosphate shunt is known to be 
significantly elevated in psoriatic tissue10), Tamer et al . 2 5 ) 
demonstrated that the "minimun structure" compound had 
an IC50-value of 9.4 ^iM which was very similar to 8 | i M for 
anthralin. 
Significance of free hydroxy group at C-l 
In accordance with the "minimum structure" concept we 
found that deriv. 1 characterized by methoxy groups at C- l 
and C-8 was not cytotoxic and inhibited the cell growth 
parameters to only a very low degree. These data are in 
good agreement with the findings for a very similar com-
pound, namely 1,8,9-trimethoxy-anthracene, which proved 
to be ineffective against psoriatic lesions39*. However, con-
trary to the "minimum structure" concept, an animal study 
by Phonier et al . 4 0 ) on 1,8,9-triacetoxy-anthracene revealed 
that the antiproliferative activity of this derivative, even 
though less than that of anthralin, did not depend on degra-
dation to a "minimum structure" compound. Thus, the study 
denied the pro-drug character of 1,8,9-triacetoxy-anthracene 
which had initially been suggested36'37'41*. Also not in favor 
of the "minimum structure" concept was the finding that the 
topically applied antiproliferatively active 1,8-diacetoxy-an-
thracene was not converted to a compound with a free C - l 
hydroxy group40). In contrast to the results with the HaCaT 
keratinocytes we recently found nonphenolic anthrones to 
be more active as inhibitors of arachidonic acid lipoxyge-
nase from bovine polymorphonuclear leucocytes than an-
thralin, suggesting a different mode of action42). 
Influence ofC-2 substitution 
Deriv. 2 and 3, which were anthrones substituted at C-2 
with acetic and propionic acid increments, respectively, did 
not reveal any cytotoxicity or inhibition of cell growth at 
the 3 |aM concentration tested. With deriv. 2 we even found 
a slightly increased cell growth. These data correspond well 
to G-6-PDH studies demonstrating rather high IC50 values 
for deriv. no. 2 (38 \xM) and 3 (18 [iM) with regard to 
anthralin (8 | iM 2 5 ) ) . 
4 and 5 are methyl esters of 2 and 3. With deriv. 4 we 
found an identical decrease of cell growth and a reduced 
cytotoxicity in comparison to anthralin. For deriv. 5 cyto-
Table 3: Protein-synthesis per culture two days after exposure of HaCaT keratinocytes to various 
test compounds. Significant differences at an overall level a < 0.05 are indicated by asterisks. 
Incubation Series 1 4 C - A m i n o Acid Incorporation 
Test Compound Percentage Statistical Comparison (p) 
(mean ± s. d.) of the Test compound 
versus 
Acetone Anthralin 
Acetone 1 100.0 ± 17.3 - 0.0000* 
Anthralin 1 16.2 ± 15.5 0.0000* -
Bian throne 1 25.0 ±21.6 0.0000* 0.0449 
Danthrone 1 91.3 ± 28.6 0.1916 0.0000* 
Deriv. 1 1 94.1 ± 19.4 0.3079 0.0000* 
Deriv. 3 1 104.1 ± 11.7 0.1708 0.0000* 
Deriv. 5 1 72.4 ± 14.6 0.0000* 0.0000* 
Deriv. 7 1 109.4 ± 11.5 0.0847 0.0000* 
Deriv. 8 1 8.0 ± 2.0 0.0000* 0.0060 
Deriv. 10 1 6.8 ± 1.6 0.0000* 0.0003* 
Deriv. 12 1 3.4 ± 1.3 0.0000* 0.0000* 
Acetone 2 100.0 ± 24.4 - 0.0000* 
Anthralin 2 25.4 ± 8.3 0.0000* -
Deriv. 2 2 119.1 ±22.0 0.0004* 0.0000* 
Deriv. 4 2 27.1 ± 6.6 0.0000* 0.4345 
Deriv. 6 2 35.8 ± 17.3 0.0000* 0.0036* 
Deriv. 9 2 12.2 ± 3.2 0.0000* 0.0000* 
Deriv. 11 2 13.0 ± 6.1 0.0000* 0.0000* 
toxicity was lacking and slowing down of cell growth was 
much less pronounced than with anthralin. 
Significance ofligands replacing one hydrogen atom at 
C-10 
The "minimum structure" concept - claiming free hydro-
gens at C-10 for clinical antipsoriatic activity - was de-
veloped from the observation that capaloin, an anthralin 
derivative glucosylated at C-10, did not clear up pso-
riasis36,37*. Our data demonstrate that this postulation does 
not have general validity. Thus, the acid 6 effected an equal 
cytotoxicity and an only slightly reduced inhibition of cell 
growth as compared with anthralin. The homologous acid 7 
was, however, completely inefficacious. Deriv. 8 and 9 are 
esters. In the case of 8 we found a decreased cytotoxicity 
with an equal inhibition of cell growth, and with 9 an equal 
cytotoxicity with a pronounced inhibition of cell growth, in 
comparison with anthralin. The ranking of drug potency by 
means of the HaCaT keratinocyte culture system was rather 
similar to that by means of the G-6-PDH assay25* for deriv. 
6, 8, and 9. In the case of 7 there was, however, a marked 
discrepancy between complete ineffectiveness in cell cul-
ture and an extremely low IC50-value of 0.9 \tfs\ in the G-6-
PDH assay, which was more than eightfold lower than the 
reference value of anthralin. 
Deriv. 8 and 9 also show activity similar to that of an-
thralin in the inhibition of leucotriene production; the acids 
6 and 7, however, were more potent than anthralin. Their 
IC5o-values for 5-lipoxygenase-inhibition were found to be 
between 5 and 10 | i M (anthralin: IC 5 0 « 40 | iM) 4 2 ) . 
Concerning anthralin derivatives bearing acyl chains of 
different length at C-10 Mustakallio43M) has already stated 
that at this position substituents less bulky than glucose do 
not hamper antiproliferative activity. Thus, in short contact 
therapy butantrone (syn. 10-butyryl-anthralin) was benefi-
cial in the treatment of psoriasis. Its efficacy as well as 
irritancy and staining were, however, less than with an-
thralin. When conventionally applied for several h per day 
over several weeks butantrone caused increased irritation as 
compared to anthralin. This was explained by a drug accu-
mulation because of retarded degradation. The compound 
lacked any pro-drug character since anthralin was not pro-
duced as evidenced by HPLC analysis45*. In HeLa cell cul-
tures the antiproliferative activity of butantrone was con-
firmed46*, as was the case for the so-called 10-acetyl-an-
thralin, another C-10-derivative, which inhibited thymidine 
incorporation in human skin fibroblasts47*. 
As a special example of C-10-liganding we studied bian-
throne which - on an equimolar base - has an identical de-
gree of cytotoxicity and growth inhibitory potency as an-
thralin. Conversely, in psoriasis Krebs and Schalte gger did 
Table 4: Activity of lactate dehydrogenase in the supernatants of keratinocyte cultures one day 
after treatment with anthralin, bianthrone, danthrone or anthralin derivatives 1 to 12 for 30 min. The 
enzyme release from cytoplasm was taken as measure for cytotoxicity implying substantial plasma 
membrane damage. Significant differences at an overall level a < 0.05 are indicated by asterisks. 
Incubation Series Lactate Dehydrogenase release 
Test Compound Percentage Statistical Comparison (p) 
(mean ± s. d.) of the Test compound 
versus 
Acetone Anthralin 
Acetone 100.0 ± 36.7 0.0000* 
Anthralin 1 641.1 ± 195.3 0.0000* -
Bianthrone 1 659.7 ± 286.2 0.0000* 1.0000 
Danthrone 1 150.1 ± 65.8 0.0625 0.0000* 
Deriv. 1 1 129.5 ± 44.2 0.2973 0.0000* 
Deriv. 3 1 75.9 ± 32.4 0.1135 0.0000* 
Deriv. 5 1 126.5 ± 42.6 0.3865 0.0000* 
Deriv. 7 1 161.7 ± 51.3 0.0188 0.0000* 
Deriv. 8 1 392.8 ± 74.3 0.0000* 0.0008* 
Deriv. 10 1 228.2 ± 73.7 0.0008* 0.0000* 
Deriv. 12 1 434.7± 156.4 0.0000* 0.0315 
Acetone 2 100.0 ± 34.7 - 0.0000* 
Anthralin 2 685.0 ± 97.8 0.0000* -
Deriv. 2 2 101.8 ± 29.6 0.6665 0.0000* 
Deriv. 4 2 416.0 ± 170.5 0.0002* 0.0012* 
Deriv. 6 2 640.1 ± 147.8 0.0000* 0.6048 
Deriv. 9 2 803.6 ± 207.5 0.0000* 0.1359 
Deriv. 11 2 712.1 ± 177.3 0.0000* 0.3401 
not observe a clearing efficacy of this dimeric com-
pound3637*, and it did not influence cell cycle kinetics in 
hairless mouse epidermis48*. With regard to former in vitro 
studies the findings for bianthrone are also conflicting. It 
thus inhibited in comparison to anthralin a) the thymidine 
incorporation, glutamine respiration and C O 2 production 
from glucose of SV-40 transformed human keratinocytes3* 
as well as mitochondrial membrane functions5* each to a 
lower degree and b) the thymidine incorporation and growth 
in human skin fibroblasts to a higher degree47,49*. Bian-
throne did not alter the migration and superoxide anion pro-
duction from human neutrophils in comparison to a solvent 
control17*. In vitro bianthrone produces the same radical 
species and decomposition products as anthralin50*. 
Significance ofligands replacing both hydrogens at C-10 
Deriv. 10,11, and 12 bear lacton rings at C-10 consisting 
of four, five and six C-atoms, respectively. The keratinocyte 
growth inhibitory efficacy of all three derivatives exceeded 
that of anthralin, and deriv. 11 exerted the maximum effect 
ever recorded in our experiments. Therefore, it seems to be 
excluded that these anthralin derivatives act as pro-drugs by 
degradation to anthralin. In good agreement with these re-
sults is the finding that deriv. 10 to 12 are potent lipoxyge-
nase inhibitors, as well42*. Their ICso-values were found to 
be about 2 | i M in our test system for derivatives 11 and 12; 
deriv. 10 was slightly less active (IC 5 0 « 3 |iM). We found 
an identical cytotoxicity for deriv. 11 and 12 as compared to 
anthralin; a to some extent lower cytotoxic effect was only 
found in the case of deriv. 10. 
With regard to substitution of both hydrogens at C-10, 
danthrone, clinically lacking any antipsoriatic quality36,37*, 
may be regarded as a special case. Under our assay condi-
tions this degradation product did not reveal any cytotox-
icity. We found only a very minor inhibition of cell growth. 
In the micromolar range of concentration danthrone was, 
however, completely inactive concerning the proliferation 
as well as glucose- and glutamine-metabolism in keratino-
cyte cultures3*, the thymidine incorporation in fibroblasts47* 
and the motility and superoxide anion generation of neutro-
phils17*. Concerning a multifunctional analysis of the inter-
action with the inner mitochondrial membrane danthrone is 
found to be almost inactive5*. The slight growth inhibition 
effects observed in the HaCaT cells under danthrone might 
be explained by their especially high sensitivity due to a 
relatively short population doubling time of 21 h under the 
subconfluent growth conditions26*. 
Conclusion 
There is good evidence by clinical and in vitro studies on 
different compounds (i.e. anthralin, danthrone, butantrone) 
that the antipsoriatic efficacy of a drug may be tested by its 
antiproliferative and cytotoxic effects in cell cul-
tures1'3,29,46*. Employing such a keratinocyte assay the pres-
ent results on anthralin derivatives mostly reveal a good 
correlation with the results gained by evaluating com-
pounds' effects on G-6-PDH activity25*. There was only one 
compound [7] with a striking discrepancy between the cell 
culture and the enzyme assays. In the case of anthralin the 
sensitivity of the enzyme system (IC 5 0 = 8|iM25*) is much 
lower as compared to the more complex HaCaT keratino-
cyte system (IC50 = 0.2 | i M for 3H-thymidine-incorpora-
tion27*). This obviously excludes G-6-PDH as a primary tar-
get for the drug's action. This conclusion is corroborated by 
studies concerning the intracellular distribution of 1 ^ -an-
thralin, revealing that the cytosol remained essentially un-
labeled3*. 
Substitution not only at C- l (deriv. 1) and C-10 (deriv. 7) 
of the anthrone skeleton but also at C-2 (deriv. 3) may cause 
loss of efficacy, and, paradoxically, with an acetic acid l i -
gand at C-2 (deriv. 2) we even observed a slight stimulation 
of cell growth. Among the anthralin derivatives tested we 
found seven compounds (deriv. 4, 6, 8, 9,10,11,12) exert-
ing cell growth inhibitory and cytotoxic effects approximat-
ing or exceeding those of anthralin. For future investigations 
these substances would be of special interest as hydrophilic 
anthralin model compounds and antipsoriatic drugs. 
The skillful technical assistance of Mrs. G. Franck and Mrs. V. Schloss-
berg is gratefully appreciated. 
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